Future studies on SGLT2 inhibitors will likely continue to focus on heart failure and diabetic cardiomyopathy, and conduct more in-depth analysis of molecular mechanisms, especially those related to fibrosis and AMPK. The gene discussed is SLC5A2; the disease is diabetic cardiomyopathy.